Three-year outcomes for Dolutegravir (DTG) plus Lamivudine (3TC) in ARTnaive and pre-treated people living with HIV-1 (PLHIV) in Germany: Real-world data from the German URBAN cohort

被引：0
|
作者：
Noe, S. [1 ]
Scholten, S. [2 ]
Wyen, C. [3 ]
Sabranski, M. [4 ]
Postel, N. [5 ]
Degen, O. [6 ]
Beer, D. [7 ]
Ummard-Berger, K. [8 ]
Westermayer, B. [9 ]
Dymek, K. M. [10 ]
Scherzer, J. [10 ]
机构：
[1] IMVZ Munchen Goethepl, Munich, Germany
[2] Praxis Hohenstaufenring, Cologne, Germany
[3] Praxis Ebertpl, Cologne, Germany
[4] ICH Study Ctr, Hamburg, Germany
[5] Prinzmed, Munich, Germany
[6] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[7] Praxis Dr H Knechten, Aachen, Germany
[8] UBN Praxis, Berlin, Germany
[9] GSK, Munich, Germany
[10] ViiV Healthcare, Munich, Germany
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
EACS2023:
引用
收藏
页码：137 / 139
页数：3
相关论文
共 15 条
  • [1] Two-year outcomes of dolutegravir (DTG) plus lamivudine (3TC) in ART-naive and pre-treated people living with HIV in Germany: real-world data from the German URBAN cohort
    Beer, D.
    Scherzer, J.
    Noe, S.
    Scholten, S.
    Wyen, C.
    Postel, N.
    Degen, O.
    Sabranski, M.
    Westermayer, B.
    Dymek, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 112 - 113
  • [2] 12-month outcomes of dolutegravir (DTG) plus lamivudine (3TC) in ART-naive and pre-treated people living with HIV in Germany: real-world data from the German URBAN cohort
    Scholten, S.
    Noe, S.
    Wyen, C.
    Beer, D.
    Postel, N.
    Degen, O.
    Pauli, R.
    Hillenbrand, H.
    Westermayer, B.
    Dymek, K. M.
    Scherzer, J.
    HIV MEDICINE, 2021, 22 : 111 - 112
  • [3] Real-world data from the prospective URBAN cohort study on the use of dolutegravir (DTG) plus lamivudine (3TC) in ART-naive and pre-treated people living with HIV in Germany
    Postel, N.
    Schneeweiss, S.
    Wyen, C.
    Schabaz, F.
    Degen, O.
    Weinberg, G.
    Sabranski, M.
    Ummard-Berger, K.
    Dymek, K.
    Westermayer, B.
    Scherzer, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 48 - 49
  • [4] 2-Year outcomes of dolutegravir plus lamivudine in ART-naive and pre-treated people living with HIV in Germany: Real-world Data From the URBAN Cohort
    Beer, Daniel
    Scherzer, Jenny
    Noe, Sebastian
    Scholten, Stefan
    Wyen, Christoph
    Postel, Nils
    Degen, Olaf
    Sabranski, Michael
    Westermayer, Bernd
    Dymek, Kathrin M.
    Baum, Alexander
    HIV MEDICINE, 2023, 24 : 28 - 30
  • [5] Two year outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected PLHIV: real-world data from the German JUNGLE cohort
    Ummard-Berger, K.
    Wyen, C.
    Schabaz, F.
    Hillenbrand, H.
    Beer, D.
    Schneeweiss, S.
    Weinberg, G.
    Postel, N.
    Westermayer, B.
    Dymek, K. M.
    Scherzer, J.
    HIV MEDICINE, 2021, 22 : 76 - 76
  • [6] Treatment-emergent integrase strand transfer inhibitor (INSTI) resistance-associated mutations among people living with HIV-1 treated with dolutegravir (DTG) plus lamivudine (3TC) with pre-existing M184V/I from real-world and interventional studies
    Fox, Dainielle
    Blick, Gary
    Mesplede, Thibault
    Verdier, Gustavo
    Calderon, Monica
    Parry, Chris M.
    Grove, Richard
    Letang, Emilio
    Priest, Julie
    Jones, Bryn
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 291 - 292
  • [7] Three-year outcomes of dolutegravir/rilpivirine in virologically suppressed HIV-infected PLWHIV: real-world data from the prospective German JUNGLE cohort
    Schabaz, F.
    Scherzer, J.
    Schneeweiss, S.
    Beer, D.
    Ummard-Berger, K.
    Pauli, R.
    Wyen, C.
    Hillenbrand, H.
    Westermayer, B.
    Dymek, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 85 - 86
  • [8] Real world data of using Triumeq (dolutegravir/abacavir/lamivudine; DTG/ABC/3TC): final outcomes of the 3-year German TRIUMPH cohort show good virologic effectiveness and safety in clinical routine
    Postel, N.
    Heuchel, T.
    Malfertheiner, P.
    Brust, J.
    Scholten, S.
    Stephan, C.
    Bohr, U.
    Hillenbrand, H.
    Lutz, T.
    Glaunsinger, T.
    Westermayer, B.
    Lueftenegger, D.
    Walli, R-K
    HIV MEDICINE, 2019, 20 : 81 - 82
  • [9] Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection: 3-year results from the GEMINI studies
    Cahn, P.
    Sierra-Madero, J.
    Arribas, J.
    Antinori, A.
    Ortiz, R.
    Clarke, A.
    Hung, C.
    Rockstroh, J.
    Girard, P.
    Sievers, J.
    Man, C.
    Urbaityte, R.
    Underwood, M.
    Pappa, K.
    Smith, K.
    Gartland, M.
    Aboud, M.
    van Wyk, J.
    Wynne, B.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 29 - 29
  • [10] Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection: 3-year results from the GEMINI studies
    Cahn, Pedro
    Madero, Juan Sierra
    Arribas, Jose
    Antinori, Andrea
    Ortiz, Roberto
    Clarke, Amanda
    Hung, Chien-Ching
    Rockstroh, Juergen
    Girard, Pierre-Marie
    Sievers, Jorg
    Man, Choy
    Urbaityte, Rimgaile
    Underwood, Mark
    Pappa, Keith
    van Wyk, Jean
    Wynne, Brian
    HIV MEDICINE, 2021, 22 : 30 - 30
12